Theravance Biopharma
TBPH
TBPH
116 hedge funds and large institutions have $655M invested in Theravance Biopharma in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 28 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
2.03% less ownership
Funds ownership: 82.56% → 80.53% (-2%)
3% less funds holding
Funds holding: 119 → 116 (-3)
76% less call options, than puts
Call options by funds: $978K | Put options by funds: $4.14M
Holders
116
Holding in Top 10
1
Calls
$978K
Puts
$4.14M
Top Buyers
| 1 | +$22.7M | |
| 2 | +$15M | |
| 3 | +$8.28M | |
| 4 |
NM
Newtyn Management
New York
|
+$7.86M |
| 5 |
D.E. Shaw & Co
New York
|
+$3.98M |
Top Sellers
| 1 | -$28.4M | |
| 2 | -$17.4M | |
| 3 | -$12.2M | |
| 4 |
Millennium Management
New York
|
-$8.04M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$5.5M |